Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03166800 · ClinicalTrials.gov registry record · Phase 1
MitoQ for Fatigue in Multiple Sclerosis
A Phase 1 study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03166800 is a Phase 1 study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 9 participants.
The verdict
NCT03166800, a Phase 1 study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after study drug initiation will assess if MitoQ has a significant change in fatigue.
Interventions
- DRUG Placebo
- DRUG Mitoquinone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-09-15 |
| Est. Completion | 2019-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03166800
The ClinicalTrials.gov registry entry for NCT03166800 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03166800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03166800 about?
NCT03166800 is a clinical study titled "MitoQ for Fatigue in Multiple Sclerosis". The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after study drug initiation will assess if MitoQ has a significan...
What is the current status of trial NCT03166800?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2018-09-15. Estimated completion is 2019-01-10.
What interventions are being tested in trial NCT03166800?
The interventions under investigation include: Placebo (DRUG), Mitoquinone (DRUG).
Who is sponsoring clinical trial NCT03166800?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.